Kornimate/medical-research-clean huggingface dataset:
stereotactic radiotherapy combined with adebrelimab and tcb (nab-paclitaxel + carboplatin) in neoadjuvant treatment of tnbc

Conditions: Stereotactic Radiotherapy; Immunotherapy; Breast Cancer

Summary: this study was an open-label, multicenter, randomized study. it is planned to include 136 patients with stage ii-iii triple negative breast cancer. eligible subjects will be randomized to receive either the experimental arm: adebrelimab plus stereotactic radiotherapy followed by adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin) or the control arm: adebrelimab plus nab-paclitaxel + carboplatin.


Eligibility criteria:
inclusion criteria: * treatment-naïve breast cancer female patients aged ≥ 18 years and ≤ 75 years; * histopathologically confirmed early or locally advanced triple-negative invasive breast cancer according to the latest asco/cap guidelines, meeting the following conditions: (1) pathological type is triple-negative, specifically: er negative: ihc \< 1%, pr negative: ihc \< 1%, her2 negative: ihc 0/1 + or ihc2 + but ish negative; * clinical stage ii-iii invasive breast cancer with measurable lesions according to recist 1.1; * ecog score 0-1; * able to tolerate preoperative and postoperative adjuvant radiotherapy after assessment by a radiologist; * appropriate level of organ function * patients voluntarily participate in and sign the informed consent form, are expected to have good compliance and cooperate with the study according to the requirements of the protocol. exclusion criteria: * patients with metastatic breast cancer or bilateral breast cancer; * patients with inflammatory breast cancer or occult breast cancer; * patients received any anti-tumor therapy within 12 months before signing the informed consent form, including chemotherapy, targeted therapy, radiotherapy, endocrine therapy, immunotherapy, biological therapy or tumor embolization; * patients previously received pd-1/pd-l1 antibody, ctla-4 antibody, or other treatments against pd-1/pd-l1 inhibitors; * female patients who are pregnant and lactating, female patients who are fertile and have a positive baseline pregnancy test, or female patients of childbearing age who are unwilling to take effective contraceptive measures throughout the trial. * have a clear history of neurological or psychiatric disorders, including epilepsy or dementia, and the subject has a known history of psychotropic drug abuse, alcoholism ; * human immunodeficiency virus (hiv) infection or known acquired immunodeficiency syndrome (aids); positive hepatitis b surface antigen (hbsag) test, or positive hepatitis b core antibody (hbcab) test followed by positive hbv-dna test (hbv-dna test was performed only in patients with negative hbsag test and positive hbcab test); positive hepatitis c virus (hcv) antibody test followed by positive hcv-rna test (hcv-rna test was performed only in patients with positive hcv antibody test) * any other condition that, in the opinion of the investigator, would make the patient inappropriate for participation in this study.
national breast cancer and lymphedema registry

Conditions: Breast Cancer; Lymphedema

Summary: the purpose of the national breast cancer lymphedema registry is to collect health information in order to study the lymphedema as a complication of breast cancer treatment. the investigators hope to learn whether early diagnosis will help to prevent lymphedema or, if it does occur, to reduce the severity.

historically, breast cancer-associated lymphedema has been relatively ignored, with mis-diagnosis, late diagnosis, and failure to treat. the condition has a measurable, substantial impact on patient function and perceived quality of life (qol). recent pilot studies suggest that interventions that are designed to facilitate early diagnosis and preventive strategies have a major impact on the incidence and severity of disease burden. this registry is designed to prospectively capture the relevant data to document the impact of preemptive diagnostic and treatment strategies.

Eligibility criteria:
inclusion criteria: * breast cancer survivorship exclusion criteria: * age \< 18 years old
clinical investigation of the dextenza 0.4mg intracanalicular insert delivery system used in cataract surgery

Conditions: Cataract

Summary: to monitor intraocular pressure in glaucoma patients after cataract surgery preformed in conjunction with minimally invasive glaucoma surgery (migs)

the purpose of this study is to monitor glaucoma patients intraocular pressure (iop) after cataract surgery performed in conjunction with minimally invasive glaucoma surgery. after qualifying for this study, subjects will be randomized in a 1:1 allocation of one of two arms. the purpose of this study is to determine if dextenza (dexamethasone) 0.4mg intracanalicular insert delivery system, provides a decreased risk of elevated post-operative iop vs. standard therapy controlled topical steroid durezol (difluprednate ophthalmic emulsion) 0.05%

Eligibility criteria:
inclusion criteria: * age 18 or older * mild-to-moderate primary open angle glaucoma and visually significant cataract with plans to undergo clear cornea cataract surgery with phacoemulsification and implantation of posterior chamber iol combined with minimally invasive glaucoma surgery ( migs) procedure in both eyes. exclusion criteria: * use of topical steroid, systemic steroid or intravitreal steroid implants within last 3 months * previous corneal surgery or pathology * active or history of chronic or recurrent inflammatory eye disease in either eye * ocular pain in either eye * proliferative diabetic retinopathy in either eye * significant macular pathology detected on macular optical coherence tomography evaluation at the screening visit in either eye. * laser or incisional ocular surgery during the study period and 6 months prior in either eye * systemic concomitant pain medication management with the pharmacology class of oxycodone * systemic nsaids use \>/=750 mg daily * clinically significant macular edema * history of cystoid macular edema in either eye
the effect of colchicine on inflammation in acs patients

Conditions: Acute Coronary Syndrome; STEMI

Summary: this study will evaluate whether the anti-inflammatory effect of colchicine is beneficial in acs patients

this study will evaluate the effect of colchicine on inflammation, cardiac remodeling, and atherosclerotic risk in stemi patients through the assessment of the il-1β, sst2, and lipid profile parameters as well as to examine the drug safety and tolerability in these patients.

Eligibility criteria:
inclusion criteria: * male or female * \>18 yrs * stemi patients who were successfully treated with pci. exclusion criteria: * pregnant or breast-feeding women or women of childbearing potential. * active inflammatory, known malignancy, infectious diseases or current treatment with corticosteroids or anti inflammatory agents. * known hypersensitivity to colchicine or current chronic treatment with colchicine. * severe renal failure (estimated creatinine clearance \<30ml/min) or hepatic failure (child pugh score b or c ) * cardiac arrest, ventricular fibrillation, cardiogenic shock or previous myocardial infarction. * patients using the following agents: strong cyp3a4 inhibitors (ritonavir, clarithromycin, ketoconazole, voriconazole, itraconazole), intermediate cyp3a4 inhibitors (aprepitant, diltiazem, erythromycin, fluconazole, verapamil), p-gp inhibitor (amiodarone, clarithromycin, erythromycin, azithromycin, ranolazine, verapamil, ketoconazole, itraconazole) and grape fruit juice

Keywords: colchicine inflammation acs stemi atherosclerosis
effectiveness and safety of topical finasteride and minoxidil combination compared to topical minoxidil for the treatment of male androgenetic alopecia

Conditions: Androgenetic Alopecia

Summary: a double-blind, randomized, controlled trial of 40 male patients with androgenetic alopecia was conducted. all subject were randomized to receive either combination of minoxidil 5% topical and finasteride 0,1% topical or minoxidil 5% topical

all subject were randomized to receive either combination of minoxidil 5% topical and finasteride 0,1% topical or minoxidil 5% topical the primary outcome was increase of the hair density and hair diameter (mean thickness) measured by trichoscan measurements were done at baseline and every four weeks for twelve weeks. additionally, side effects of therapy was also measured.

Eligibility criteria:
inclusion criteria: 1. male aged from 18-59 years diagnosed with androgenic alopecia 2. androgenic alopecia type iii-v according to hamilton-norwood criteria 3. willing to participate in this research by signing the consent form after receiving an explanation from the researcher 4. willing to not cutting the hair nor coloring the hair during the study exclusion criteria: 1. diagnosed with other infectious or inflammatory skin disease in the scalp 2. using oral medications or vitamins that aim to increase the amount of hair in the last 1 month 3. using topical medication that aim to increase the amount of hair in the last 2 weeks 4. undergoing cosmetic procedure for aga therapy such as low-level laser therapy (lllt) procedures, platelet-rich plasma (prp) injections, or microneedling within the last 3 months 5. have sexual disorder such as decreased libido 6. have a history of allergy or irritant contact dermatitis to the minoxidil and finasteride

Keywords: finasteride topical minoxidil topical male androgenetic alopecia
study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses in healthy

Conditions: Healthy Subjects; Osteoarthritis

Summary: the purpose of this study is to evaluate the safety and tolerbility of ascending multiple oral doses of agg-523 in healthy subjects and in subjects with osteoarthritis.


Eligibility criteria:
inclusion criteria: * healthy men or women, aged 18 to 40 years and subjects with osteoarthritis of the knee, aged 40 to 75 years. * women must be of non-childbearing potential, defined as surgically sterile with documentation of ultrasound. * must be nonsmoker or smoke less than 10 cigarettes per day.
eosinophils in human adipose tissue

Conditions: Obesity; Insulin Resistance

Summary: the purpose of this study is to better understand the interactions between the innate immune system, in particular eosinophils (eos), and adipose tissue (at) in human health and in disease states such as obesity and insulin resistance.


Eligibility criteria:
inclusion criteria: * obesity (bmi\>30 kg/m2). * evidence of insulin resistance as defined by hemoglobin a1c \> 5.7%. * mayo clinic patients evaluated by dr. rahul pannala. * pursue an endoscopic gastroplasty at mayo clinic arizona in the gastroenterology department. * equal distribution of gender. * 18 yo older of age. * bmi\>30 kg/m2. * nonsmoker. * taking no medication affecting glucose or lipid metabolism. * no more than 5% change in body weight in the previous 6 months. * mostly sedentary (engaging in strenuous exercise (\> 70% max hr) less than 3 times a week). * not be receiving corticosteroid therapy. * have no history of asthma, copd or atopic syndrome, or autoimmune disease (ulcerative colitis, chron's disease, eosinophilic esophagitis, any rheumatologic disease such as lupus, rheumatoid arthritis, sjogren syndrome). exclusion criteria: * \<17 years of age. * bmi \<30 kg/m2. * smoker. * taking medication affecting glucose or lipid metabolism. * greater than 5% change in body weight within the previous six months. * engage in strenuous exercise (\>70% max hr) less than 3 times a week. * receiving corticosteroid therapy. * have a history of asthma. * history of copd or atopic syndrome. * history of autoimmune disease (ulcerative colitis, chron's disease, eosinophilic esophagitis, any rheumatologic disease such as lupus, rheumatoid arthritis, sjogren syndrome).
anesthetic and dilating gel for cataract surgery

Conditions: Cataract

Summary: to prepare the eye for cataract surgery, drugs must be given to the eye to allow for surgery to take place. traditionally, dilating drops and drops containing nsaids (to control inflammation) are given to the patient well in advance of surgery at repeated time intervals. as well, a gel containing lidocaine is applied to the eye just prior to surgery to anesthetize (reduce pain and feeling) in the area of the eye. although effective, the procedure is time-consuming and costly for nursing staff. recently, a few hospitals have reported success in mixing the pupil-dilating and nsaid drops with the lidocaine gel, creating an "anesthetic dilating gel". although success has been reported, there have been no studies to clearly demonstrate that the "anesthetic dilating gel" is as effective at dilating the pupil and reducing sensitivity of the cornea during surgery than the traditional methods of drops and gel. it is possible that the dilating gel is less effective due to slower diffusion of drugs into the eye. the study will compare the effectiveness of the anesthetic dilating gel with the standard pre-operative pharmacologic regimen for cataract surgery. stability (maintaining effectiveness over time) and contamination of the study gel will also be assessed. if the dilating gel is shown to be as effective in regards to pupil dilation and corneal anesthesia, while maintaining stability and sterility over time, hospitals can be encouraged to use such a anesthetic dilating gel routinely during pre-operative procedures before cataract surgery.


Eligibility criteria:
inclusion criteria: * scheduled for first cataract surgery (i.e., first eye) exclusion criteria: * previous ocular surgery, * pseudoexfoliation syndrome, * diabetes, * herpetic eye disease, * posterior synechiae, * previous uveitis
the role of glucagon in the effects of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors

Conditions: Type 2 Diabetes

Summary: in normal physiology, glucagon from pancreatic alpha cells plays an important role in maintaining glucose homeostasis via its regulatory effect on hepatic glucose production. patients with type 2 diabetes exhibit elevated plasma glucagon levels in the fasting state, and in response to ingestion of glucose or a mixed meal.glucagon, glucagon concentrations fail to decrease appropriately and may even increase. this diabetic hyperglucagonaemia may therefore contribute importantly to the hyperglycaemia of the patients. several glucose-lowering treatment modalities have been shown to affect glucagon levels in patients with type 2 diabetes, but the role of glucagon in the glucose-lowering effects of these treatment modalities has been difficult to discern. by using a glucagon receptor antagonist (gra) the investigators will exploit glucagon receptor antagonism to delineate the role of glucagon during treatment with sodium-glucose co-transporter 2 (sglt2) inhibitors and dipeptidyl peptidase 4 (dpp-4) inhibitors, which have been shown to increase and decrease plasma glucagon levels, respectively.


Eligibility criteria:
inclusion criteria: * caucasians above 30 years of age with diet or metformin treated type 2 diabetes for at least 3 months (diagnosed according to the criteria of the world health organization) * normal haemoglobin * informed consent exclusion criteria: * inflammatory bowel disease * intestinal resections * nephropathy (serum creatinine above normal range and/or albuminuria) * liver disease (serum alanine aminotransferase (alat) and/or serum aspartate aminotransferase (asat) \>2×normal values) * treatment with medicine that cannot be paused for 12 hours * pregnancy and/or breastfeeding * family history of pancreatic islet tumours * age above 75 years * treatment with loop-diuretics (applies only to arms with empagliflozin or empagliflozin placebo) * chronic heart failure
internet enhanced, patient-centered orthopedic care: a prospective, randomized, controlled pilot trial

Conditions: Knee Injuries; Shoulder Injuries; Rotator Cuff Disease; Meniscus Tear; Patellofemoral Pain

Summary: the investigators have previously reported on patient utilization of an erehab patient education web portal that utilizes streaming, clinician prescribed video instruction to motivate and inform patients in self-care of their orthopedic condition, focusing on the importance of a home exercise program. the greatest barrier to patient use of this web-based home exercise treatment plan was the initial access to the program. the purpose of this study is to compare an internet-based patient education rehab portal (erehab) to formal physical therapy (pt) in terms of patient costs and outcomes.

this is a prospective, randomized, controlled pilot study. twenty-four patients who were candidates for a knee or shoulder orthopedic outpatient physical therapy referral were randomized to a 6-week treatment course of either pt or erehab. patients were evaluated for outcome scores (koos or dash), pain nrs-11 scores, patient subjective outcomes and cost of treatment.

Eligibility criteria:
inclusion criteria: * patient diagnosed by board certified orthopedic surgeon to be in need of formal physical therapy referral * had the ability to access and use the internet and email * english-speaking * non-pregnant adults * had not received formal physical therapy for their current diagnosis exclusion criteria: * work-related injuries * pain nrs-11 score greater than or equal to 6

Keywords: rehabilitation erehab physical therapy e-health telemedicine telerehabilitation patient-centered
methotrexate and cytosine in adult langerhans cell histiocytosis

Conditions: Langerhans Cell Histiocytosis

Summary: study type: interventional study design: endpoint classification: efficacy study intervention model: single group assignment masking: open label primary purpose: treatment purpose: this single arm clinical trial is studying efficacy and tolerance of combination chemotherapy with methotrexate and cytosine arabinoside in newly diagnosed adult with langerhans cell histiocytosis.

this single arm clinical trial is studying efficacy and tolerance of combination chemotherapy with methotrexate and cytosine arabinoside in newly diagnosed adult with langerhans cell histiocytosis.

Eligibility criteria:
inclusion criteria: 1.disease characteristics: * histopathologically confirmed diagnosis of langerhans cell histiocytosis according to the criteria defined by the histiocyte society * demonstration of cd1a antigenic determinants on the surface of lesional cells (by immunocytology or immunohistology) or birbeck granules in lesional cells by electron microscopy * considered at risk or low risk according to the following criteria: * multi-system at risk disease, defined as involvement of one or more risk organs (i.e., hematopoietic system, liver, spleen, or lungs) 1.no single-system lung involvement * multi-system low-risk disease 1.multiple organs involved but without involvement of risk organs * single-system disease 1.multifocal bone disease (i.e., lesions in 2 or more different bones) 2.localized special site involvement, such as cns-risk lesions with intracranial soft tissue extension or vertebral lesions with intraspinal soft tissue extension 3.vault lesions are not regarded as cns-risk lesions 2.patient characteristics: 1. not pregnant or nursing 2. negative pregnancy test 3. fertile patients must use effective contraception 3.prior concurrent therapy: 1. no prior treatment for langerhans cell histiocytosis exclusion criteria:

Keywords: adult with langerhans cell histiocytosis newly diagnosed methotrexate cytosine arabinoside
effect of intravenous fluid therapy on postoperative vomiting in children undergoing otorhinolaryngological surgery

Conditions: Postoperative Vomiting

Summary: the purpose of this randomized clinical trial is to evaluate the interaction of intravenous fluid therapy during otorhinolaryngological surgery, on postoperative vomiting. the hypothesis is that perioperative supplemental intravenous fluid administration reduces the incidence of postoperative vomiting.

postoperative vomiting is a common complication on pediatric surgery, especially otorhinolaryngological surgery. is one of the main reasons of prolonged hospital stay, and also a cause of patient´s discomfort and an increase on hospitalization cost. there are studies in adults with inconclusive results related to supplemental fluid therapy and decrease of postoperative nausea and vomiting. but, in recent years a study in children showed favorable results in strabismus surgery. the foundation of this study consist in that hypovolemia may possibly cause a decrease in perfusion causing intestinal hypoxia, which in turn increase the incidence of nausea and vomiting. the objective of this study is to observe the effect of supplemental fluid therapy on postoperative vomiting on otorhinolaryngological surgery.

Eligibility criteria:
inclusion criteria: * asa physical status i or ii * age 1-12 yr * scheduled for elective tonsillectomy or adenotonsillectomy exclusion criteria: * history of diabetes * history of mental retardation * obesity (bmi ≥95th percentile for age and sex) * intake of antiemetic or psychoactive medication within 24 hours before surgery * known gastroesophageal reflux
thalidomide and dacarbazine for metastatic melanoma

Conditions: Melanoma

Summary: the purpose of this clinical trial is to assess the activity of thalidomide in combination with dacarbazine (dtic) in patients with metastatic melanoma. safety and toxicity of the two drugs will also be assessed. dacarbazine is the standard medical treatment for metastatic melanoma. it has been shown to produce tumor shrinkage in approximately 20% of patients with advanced melanoma. this shrinkage is usually incomplete and lasts a short time. thalidomide is a drug that inhibits tumor blood vessel growth. it can be given orally. it is hoped that this combination can be given to patients with metastatic melanoma without causing too much toxicity while increasing the response rate.


Eligibility criteria:
inclusion criteria: * patients with metastatic melanoma. * lesions must be measurable. * patient must have the following minimum labs: anc\> 1500/mm3, hemoglobin \> 8 mg/dl; platelets \> 100,000 mm3; and liver function tests \< 5x normal; and creatinine \< 1.5 mg/dl. * ecog performance status \> 2. * no prior therapy with dtic or thalidomide * no other history of malignancy other than curatively resected basal cell carcinoma of the skin or carcinoma in situ of the cervix. * patients must not be pregnant or lactating. * sexually active men and women of childbearing age must use adequate contraception. all patients must understand the potential for severe birth defects with thalidomide and must be able to follow instructions to avoid conception while taking thalidomide